Webinar – Rare & Null Allele Detection with HLA Twin™

04/12/2014

Are you interested in Orthogonal Bioinformatic Validation? Watch this latest webinar presentation on HLA Twin™ – Rare & Null Allele Detection Date: Thursday, 11th December, 2014 Time: 12:00–1pm EST (6–7pm CET) A live Q&A session will follow the presentation, offering you the opportunity to put forward any questions. Following registration, you will...

Patient Stratification in Clinical Trials

01/12/2014

When carrying out clinical trials, one of the most important logistical and statistical challenges is ensuring that your data accurately reflects the population you are setting out to study. None of us has the resources to test a drug on the entire human race, but if we want to have...

Omixon Signs Letter of Intent with Pronto Diagnostics

10/11/2014

At Omixon we are working hard to expand our customer base. Our Holotype HLA kit is already making an impact on the HLA typing market, and we are regularly contacted by companies proposing to partner with us as local distributors. For example, we have recently signed a letter of intent with Pronto Diagnostics and...

Omixon Celebrates a Frighteningly Successful ASHI 2014 in Denver

31/10/2014

Omixon took a team of scary mad scientists, zombie marketeers, and bloodsucking vampires (sales people) to Denver, Colorado, to the 40th Anniversary Meeting for the American Society of Histocompatibility and Immunogenetics (ASHI). Joining the team were a couple of respectable Omixon board members, who were neither undead nor scary (except...

SeqGene is Omixon’s New Distributor

15/10/2014

Omixon is pleased to announce the signature of a Distribution Agreement with SeqGene, based in Taipei City, Taiwan. The agreement is effective 1st October, 2014. About SeqGene: SeqGene is a molecular biology company. They specialize in next generation sequencing (NGS)-based services for oncology studies and HLA typing. The company is...